john farley

AMA Update 151: Paxlovid side effects, treatment timelines and more with John Farley, MD, MPH

23 de mayo de 2022 casimedicos AMA Update 00:13:45 0 Comments

AMA CXO Todd Unger discusses what physicians and patients need to know about Paxlovid with John Farley, MD, MPH, director of the Office of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs at the FDA.

For more information on Paxlovid from the FDA, visit: https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers

Read More

AMA Update 123: The FDA on Monoclonal Antibody Therapeutics: What physicians need to know, Part I

11 de febrero de 2022 casimedicos AMA Update 00:10:04 0 Comments

AMA president Gerald Harmon, MD, welcomes experts from the U.S. Food and Drug Administration (FDA) to discuss what prescribers need to know about COVID-19 therapeutic drugs, Paxlovid and Molnupiravir. Alternative treatment options for high-risk outpatients with mild-moderate COVID-19 are also discussed.

Guest: John Farley, MD, MPH, director, Office of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA

Read More